Trevi Therapeutics (TRVI) Other financing activities (2018 - 2025)
Trevi Therapeutics' quarterly Other financing activities came in at $219000.0 in Q3 2025, down 40.49% quarter-over-quarter from $368000.0 in Q2 2025.
Trevi Therapeutics has reported Other financing activities for 8 years, with the latest figure at $219000.0 in Q3 2025.
- For the quarter ending Q3 2025, Other financing activities changed N/A year-over-year to $219000.0; the trailing twelve-month figure through Dec 2025 stood at $809000.0 (down 94.37% YoY), and the FY2025 full-year result was $809000.0, down 94.28% from the prior year.
- Other financing activities for Q3 2025 stood at $219000.0, down from $368000.0 in the prior quarter.
- The five-year high for Other financing activities was $14.1 million in Q4 2024, with the low at -$1.5 million in Q4 2023.
- Average Other financing activities over 5 years is $1.2 million, with a median of $100000.0 recorded in 2021.
- Year-over-year, Other financing activities tumbled 107.67% in 2022 and surged 1074.24% in 2024.
- Tracing TRVI's Other financing activities over 5 years: stood at $100000.0 in 2021, then sank by 123.0% to -$23000.0 in 2022, then slumped by 6213.04% to -$1.5 million in 2023, then surged by 1074.24% to $14.1 million in 2024, then tumbled by 98.45% to $219000.0 in 2025.
- The last three Other financing activities figures came in at $219000.0 (Q3 2025), $368000.0 (Q2 2025), and $222000.0 (Q1 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn |
| 10 | Trevi Therapeutics | 2.02 Bn | 1.85 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2025 | 219,000.00 |
| Sep 30, 2025 | 219,000.00 |
| Jun 30, 2025 | 368,000.00 |
| Jun 30, 2025 | 368,000.00 |
| Mar 31, 2025 | 222,000.00 |
| Mar 31, 2025 | 222,000.00 |
| Dec 31, 2024 | 14.15 Mn |
| Dec 31, 2024 | 14.15 Mn |
| Dec 31, 2023 | -1.45 Mn |
| Dec 31, 2023 | -1.45 Mn |
| Sep 30, 2023 | 1.68 Mn |
| Sep 30, 2023 | 1.68 Mn |
| Jun 30, 2023 | 13,000.00 |
| Jun 30, 2023 | 13,000.00 |
| Mar 31, 2023 | 15,000.00 |
| Mar 31, 2023 | 15,000.00 |
| Jun 30, 2022 | -23,000.00 |
| Jun 30, 2022 | -23,000.00 |
| Mar 31, 2022 | 44,000.00 |
| Mar 31, 2022 | 44,000.00 |
| Sep 30, 2021 | 100,000.00 |
| Sep 30, 2021 | 100,000.00 |
| Jun 30, 2021 | 300,000.00 |
| Jun 30, 2021 | 300,000.00 |
| Mar 31, 2021 | 31,000.00 |
| Mar 31, 2021 | 31,000.00 |
| Dec 31, 2020 | 3.08 Mn |
| Dec 31, 2020 | 3.08 Mn |
| Sep 30, 2020 | 11,000.00 |
| Sep 30, 2020 | 11,000.00 |
| Sep 30, 2019 | 138,000.00 |
| Sep 30, 2019 | 138,000.00 |
| Dec 31, 2018 | 20,000.00 |
| Dec 31, 2018 | 20,000.00 |
| Sep 30, 2018 | 1,000.00 |
| Sep 30, 2018 | 1,000.00 |
| Jun 30, 2018 | 20,000.00 |
| Jun 30, 2018 | 20,000.00 |
| Mar 31, 2018 | -8,000.00 |
| Mar 31, 2018 | -8,000.00 |